Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer

NCT05784974 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Cadonilimab

Sponsor

The First Hospital of Jilin University